Marc Ullman was quoted in the Nutraingredients-usa.com article, “CRN ends NAD funding, but value of claims evaluation program will go on.”

Click here to read the article.

Marc Ullman spoke with NutraingredientsUSA.com about the impact of the ABH recall on the entire nutritional supplements industry, as thousands of products were recalled as part of a consent decree, which covered 859 businesses and brands. ABH is a contract manufacturer that was sanctioned by the FDA for repeatedly failing to comply with regulations.

Marc

HACKENSACK, NJ  – – Rivkin Radler LLP is pleased to announce that Nancy A. Del Pizzo, Jenna Gabay and Gene Kang, have been named 2020 New Jersey Super Lawyers.  Del Pizzo was named a Top Rated Intellectual Property Litigation Attorney; and Gabay and Kang were named Rising Stars.

A partner in the firm’s Commercial Litigation;

On Thursday, May 7, 2020, Benjamin Malerba and Jeff Kaiser will participate in a panel discussion sponsored by the Long Island Chapter of the Association of Certified Fraud Examiners.

The program, to be held at the Westbury Manor, will feature a panel of experts discussing the detection and prosecution of healthcare fraud.

For details and

Marc Ullman was interviewed for an article in Natural Products Insider entitled “Supplement contract manufacturing recall ‘unprecedented.'”

The article discusses how ABH, along with 859 of its nutritional products brands, was shut down by a U.S. Department of Justice consent decree.

To read the article, click here.

On Thursday, January 30, 2020, Steven Shapiro will present to the New York State Bar Association’s Food, Drug and Cosmetic Law Section as part of its Off-Label Promotion Update. His presentation is entitled “Promotion of CBD following Epidiolex for Rx, OTC drugs and other products.

For information and to register, click here.

On January 29, 2020, Marc Ullman’s opinion piece, “FDA’s lack of CBD guidance is a disservice to Long Island firms,” appeared in Long Island Business News.

Marc notes that an exploding market for CBD products has created a conundrum for companies wishing to cash in. Either they obey FDA’s regulations and lose out, or they break

Marc Ullman spoke with Nutraingredients-USA about a recall of 1,200 products manufactured by Edgewood, NY-based ABH Nature’s Products, Inc. (also doing business as ABH Pharma, Inc. and Stocknutra.com, Inc.). The company issued a recall under a consent decree with the United States District Court for the Eastern District of New York.

The recall is intended to

Marc Ullman spoke to Nutraingredients-USA about a new bill that would include CBD in the definition of dietary supplements in the federal Food, Drug and Cosmetic Act. The legislation is an attempt to cope with the raft of products now on the market that are technically illegal.

Marc said he thinks the bill will only

Marc Ullman was quoted in a Nutraingredients-USA story entitled “Warning letter analysis shows FDA has target on CBD, not hemp.”

To read the article, click here.